Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nano Regulatory News (ONT)

Share Price Information for Oxford Nano (ONT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 90.00
Bid: 89.25
Ask: 89.65
Change: 3.45 (3.99%)
Spread: 0.40 (0.448%)
Open: 86.75
High: 93.00
Low: 86.70
Prev. Close: 86.55
ONT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ONT shows new high-accuracy, high-output chemistry

30 Mar 2022 14:00

RNS Number : 6350G
Oxford Nanopore Technologies plc
30 March 2022
 

Oxford Nanopore technology update: CTO Clive G Brown unveils latest sequencing chemistry with highest performance to date, Short Fragment Mode and latest methylation performance evaluations  

 

30th March 2022 

 

Clive G Brown, CTO, Oxford Nanopore Technologies, reviews some of the latest technology updates during a webinar today. Highlights include performance and base modification calling improvements, as well as updates on the recently-released Short Fragment Mode (SFM) and a new basecaller. 

 

Summary:  

Latest chemistry enables 99.3% raw read accuracy at high data yields; new Kit 14 and flow cells containing R10.4.1 pore will be provided as an upgrade to the current Kit 12 chemistry and R10.4 pore, and eventually replace the R9 chemistry versions Remora, a tool that offers real time methylation analysis is shown to outperform bisulfite sequencing Short Fragment Mode is now allowing users to choose fragments from 20 bases long to millions; methylation analysis of shorter fragments enabled New basecaller, Dorado, introduced to support high performance and broader hardware compatibility 

 

Updates in sequencing chemistry to enhance performance

 

Nanopore sequencing enables the analysis of native DNA/RNA and sequencing of any length fragment from short to ultra-long, enabling the elucidation of all types of genetic and epigenetic variants.

  

Oxford Nanopore continuously drives further performance enhancements by iterating its technology to deliver improving raw read accuracy. Since 2021, users have been able to achieve >99% raw read accuracy using the most recent Kit 12 chemistry and R10.4 pore, and today Clive Brown introduces chemistry updates that bring improved data output alongside delivery of >99% raw read accuracy.  

 

The Oxford Nanopore team has successfully modified the pore, motor and run conditions to increase speed that DNA/RNA is passed through the nanopore, therefore increasing the data yield while retaining high-accuracy data. This latest update will be included in a new kit (Kit 14), to be used alongside a new pore (R10.4.1) which has been shown to achieve 99.3% raw read accuracy, whilst maintaining speeds of 420 bases per second - a similar speed to the current high-yield R9.4.1 flow cells. 

 

Further to this, to provide users with everything they need in one kit, Kit 14 will allow users to tune their accuracy and output needs by modifying the run conditions, which will be programmable in the software. Early work has shown that the highest raw accuracy (99.6%) can be achieved when run at 28 degrees. At 35 degrees, it's possible to maintain >Q20 raw accuracy (99.3%) whilst generating a higher yield. 

 

The Duplex method, where template and complement strands are paired informatically, is also improved with the new chemistry, with users now able to achieve >Q30 modal accuracy following kit updates.  

 

As the R10 pores and compatible chemistries continue to improve, Oxford Nanopore plans to discontinue the R9 pore. This is expected to be towards the end of 2023, ensuring parity of kit performance across all technology applications and allowing for a suitable transition period, through which users will be supported.

 

Real time methylation analysis 

 

Nanopore sequencing of native DNA/RNA enables users to gain information about base modifications alongside nucleotide sequence. Clive reviews the recent release of Remora - Oxford Nanopore's latest methylation analysis tool -which further enhances base-modification analysis on nanopore devices and will be integrated into MinKNOW soon, enabling much greater access to methylation data in real time. 

 

Clive shares data demonstrating clear benefits of nanopore sequencing using Remora over bisulfite treatment with short read sequencing. The data showed that when tested on five oligos representing regions of the human genome, the modifications were called with 99.8 % accuracy using nanopore compared to 98.6 % with bisulfite, where methylation analysis with nanopore sequencing required no additional up-front processes or cost.

 

Additionally, nanopore sequencing can differentiate between modifications such as 5mC and 5hmC and novel modifications can be trained into the algorithms as these become fully characterised, ensuring a complete methylation picture from a single experiment. 

 

Sequence any length fragment of DNA 

 

Oxford Nanopore's technology sequences DNA or RNA molecules of any length, from short to ultra-long. It is the only technology on the market capable of sequencing DNA lengths spanning five orders of magnitude in a single technology. However, software configurations have historically been chosen to avoid shorter strands to minimise "adapter only" reads.  

 

Last week, Short Fragment Mode (SFM) was released into the operating software, MinKNOW, and is designed to allow reads as short as 20 bases. Oxford Nanopore have demonstrated over 250M native human reads, with an average read length ~ 200 bases, on a PromethION flow cell. 

 

Following analysis of Clive's own genome and cell-free DNA isolated from plasma - the 'cf Cliveome' - using SFM, the team uncovered interesting biology, including plausible tissue typing from methylation data and greater insight into nucleosome arrangements.  

 

Other updates 

 

Clive also introduces Dorado - a new basecalling framework that will ultimately speed up access for users. Dorado is designed with support for Apple GPUs and new NVIDIA hardware. It is also projected to keep up with high accuracy (HAC) models on PromethION 48. 

 

He also briefly touched on adaptive sampling - real time selection of regions of interest using system software - on the high-output PromethION device. This will be available soon as a beta feature and is already available for users of the benchtop GridION and palm sized Mk1C devices.

 

The PromethION device can currently turn around a keep/reject decision in the time it takes for 1000 bases to pass through a nanopore. It is expected to reach GridION levels of ~200 bases with further firmware development. 

 

Further updates will be provided at our nanopore sequencing conference, London Calling, in May 2022.

 

Forward-looking statements

This announcement contains certain forward-looking statements. Phrases such as "potential", "expect", "intend", " believe we can", "working to", "anticipate", "when validated", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business, and by definition address matters that are, to different degrees, uncertain and may involve factors beyond our control.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAJMMTTMTAJBJT
Date   Source Headline
21st Jun 20245:33 pmRNSIssue of Equity and Total Voting Rights
21st Jun 202410:00 amRNSAdmission to Trading on the London Stock Exchange
19th Jun 20247:00 amRNSIssue of Equity
11th Jun 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
10th Jun 20244:00 pmRNSResult of AGM; Director Responsibilities
7th Jun 20244:00 pmRNSPDMR/PCA Notification
3rd Jun 20244:00 pmRNSIssue of Equity and Total Voting Rights
23rd May 20248:00 amRNSLondon Calling Technology Update
13th May 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st May 20245:00 pmRNSIssue of Equity and Total Voting Rights
1st May 20247:00 amRNSDirector/PDMR Shareholding
30th Apr 20247:00 amRNSPublication of Annual Report and Notice of AGM
12th Apr 20241:00 pmRNSStudy unlocks insights into disease and longevity
12th Apr 202412:00 pmRNSLTIP and DBP; Director/PDMR Notification
11th Apr 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
8th Apr 20244:00 pmRNSBlock Listing Interim Review
2nd Apr 20242:00 pmRNSIssue of Equity and Total Voting Rights
28th Mar 20245:55 pmRNSHolding(s) in Company
12th Mar 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Mar 20247:00 amRNSOxford Nanopore to Present at Barclays Conference
8th Mar 202412:00 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
6th Mar 20247:00 amRNSFY23 Preliminary Results
1st Mar 20242:00 pmRNSIssue of Equity and Total Voting Rights
29th Feb 20246:00 pmRNSDirectorate Change
13th Feb 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
2nd Feb 20244:30 pmRNSHolding(s) in Company
1st Feb 202412:00 pmRNSIssue of Equity and Total Voting Rights
22nd Jan 20247:00 amRNSExpansion of leadership team
11th Jan 20245:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
11th Jan 20245:30 pmRNSEmployee Stock Purchase Plan - PDMR Notification
9th Jan 20247:00 amRNSFY23 trading update
3rd Jan 20247:00 amRNSPresentation at 42nd Annual J.P. Morgan Conference
19th Dec 20232:00 pmRNSAppointment of Two Non-Executive Directors
12th Dec 20235:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
7th Dec 20234:30 pmRNSNanopore Community Meeting Technology Update
1st Dec 20235:00 pmRNSIssue of Equity and Total Voting Rights
30th Nov 20237:00 amRNSNational Australian rare disease programme
13th Nov 20235:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
13th Nov 202312:00 pmRNSParticipation in upcoming investor conferences
7th Nov 20238:30 amRNSAdmission to Trading on the London Stock Exchange
6th Nov 20237:00 amRNSIssue of Equity
1st Nov 20234:00 pmRNSIssue of Equity and Total Voting Rights
31st Oct 20237:00 amRNSApple showcases Oxford Nanopore in M3 launch
26th Oct 20236:10 pmRNSHolding(s) in Company
24th Oct 202312:30 pmRNSHolding(s) in Company
23rd Oct 20238:30 amRNSAdmission to Trading on the London Stock Exchange
23rd Oct 20238:30 amRNSIssue of Equity and Total Voting Rights
19th Oct 20237:00 amRNSCapital Markets Day - ONT expands into clinical
19th Oct 20237:00 amRNSbioMérieux makes investment in Oxford Nanopore

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.